Aligos Therapeutics (ALGS) Q3 2026 earnings review
Aligos advances its hepatitis trial, but cash runs short
Aligos Therapeutics, a clinical-stage developer of liver and viral drugs, slowed its research spending as its main hepatitis B trial moved past peak enrollment. Research costs fell 21% to $19 million, helping narrow the quarterly net loss to $22 million. Collecting a $25 million licensing payment from Chinese partner Amoytop in July kept cash steady at $31 million, which chief executive Lawrence Blatt expects will fund operations into the first quarter of 2027.
| Ending cash and investments | $31.1M $30.4M last quarter (after $25M July upfront) |
|---|---|
| Cash runway outlook | Into Q1 2027 2–3 quarters short of late Q3 2027 data |
| Research and development spending | $18.9M -21% from a year ago |
| B-SUPREME patients past 48 weeks | 70 29% of 245 enrolled participants |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because extending the cash runway by one quarter still leaves the biotech short of the money needed to reach its main trial readout. On the positive side, 70 of the 245 patients in the Phase 2 pevifoscorvir sodium study have completed 48 weeks of treatment, and Amoytop began Phase 1 testing for a second hepatitis B drug in China. One caution: the company burned $24 million in the quarter by our math before counting the July licensing payment, leaving less than two quarters of cash on hand.
The question now is how Aligos will bridge the two-to-three quarter funding gap between early 2027 and its late third-quarter 2027 trial results. Either the company secures another licensing deal or debt facility to avoid issuing shares, or it must raise equity before its cash runs out. A financing or partnering announcement before the first quarter of 2027 will settle how much dilution shareholders face.
🐂 Bull Case
Lead Hepatitis Study Passed One-Quarter Treatment Completion
Aligos rests its business on pevifoscorvir sodium, an oral pill designed to stop the hepatitis B virus from building its protective shell. The company is testing the drug against standard therapy over 48 weeks in a Phase 2 trial called B-SUPREME, which finished enrolling 245 patients last quarter.
Chief executive Lawrence Blatt said that "With enrollment complete and 70 participants having completed 48 weeks of treatment, the study continues to progress toward the anticipated topline data readout." Because enrollment is finished, research and development spending dropped 21.1% from a year ago to $18.9 million, which Aligos said was "primarily due to an decrease in third-party expenses for the pevifoscorvir sodium Phase 2 clinical trial."
Having 28.6% of patients finish the 48-week dosing period by our math reduces the operational cost of finishing the study. Lower quarterly trial bills slow the company's cash drain while patients complete their remaining visits.
What to watch: the number of patients completing 48 weeks of treatment in the fourth-quarter report. Reaching all 245 patients on schedule in the first half of 2027 would keep the late third-quarter readout on track.
Partner Amoytop Moved Second Drug Into Clinic
Aligos partnered with Chinese drugmaker Amoytop to fund and test ALG-170675, an injected genetic medicine for chronic hepatitis B, across Greater China. Under the deal, Amoytop pays for Chinese clinical trials while the US biotech keeps the rights to use that clinical data for regulatory filings in the rest of the world.
In the third quarter, the company reported that "Our partner Amoytop advanced ALG-170675 into Phase 1 clinical studies." Customer revenue rose to $2.8 million from $0.7 million a year ago, matching the $3.0 million milestone payment expected after Chinese regulators cleared the trial in July.
This partnership gives the drug developer human safety and dosing data on a second hepatitis B treatment without spending its own cash on the trial. That preserves Aligos's own funds for its main Phase 2 study.
What to watch: the start of the chronic hepatitis B patient cohort in China, which the company previously planned for the fourth quarter of 2026. Dosing patients after the healthy volunteer stage would move the drug toward a potential combination trial.
🐻 Bear Case
Cash Runs Out Two Quarters Before Data
Blatt said that "This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late Q3 2027." Yet the company only expects its $31.1 million in cash to fund planned operations "into the first quarter of 2027."
Cash rose slightly from $30.4 million in June only because Aligos collected a $25.0 million upfront licensing payment from Amoytop in July. Without that one-time payment, the company burned $24.3 million in the third quarter by our math, keeping pace with the first half's $48.1 million cash drain.
- Ending cash and investments: $31.1 million, down from $77.8 million at year-end 2025
- Quarterly cash burn excluding the July upfront payment: $24.3 million by our math
- Quarterly operating loss: $21.9 million, even with $18.9 million in lower R&D costs
- Unfunded gap to late Q3 2027 readout: roughly two to three quarters of operations
Even with lower clinical trial bills, a $31.1 million balance against a $21.9 million quarterly operating loss leaves the biotech short of the cash needed to reach late Q3 2027. Unless it raises fresh equity, borrows money, or sells more regional drug rights within the next few months, it cannot fund operations to see the trial results.
What to watch: a financing announcement or licensing agreement before first-quarter 2027 cash exhaustion. Raising at least $30 million to $40 million is required to bridge the company to the third-quarter 2027 trial results.
Interim Readout and Secondary Programs Remain Unmentioned
Earlier this year, Aligos told investors to expect a second interim analysis of the B-SUPREME trial in the second half of 2026, once half of the HBeAg-positive patients finished 24 weeks of treatment. It also spent nearly two years evaluating partnership options for ALG-055009, an experimental liver and weight-loss pill.
For a second straight quarter, the earnings release omitted any mention of the HBeAg-positive interim analysis, even though 70 patients across the study have already completed 48 weeks. The release also dropped all mention of ALG-055009 and the older coronavirus program, leaving the company entirely reliant on its two hepatitis B candidates.
What to watch: the quarterly Form 10-Q filing for any update on the second interim analysis and program-by-program research spending. Another quarter with near-zero spending on the liver pill would confirm that Aligos has shelved its non-viral pipeline.
Risks This Quarter Didn't Answer
Three standing business and clinical risks had no new data in the third-quarter release because the lead trial remains blinded until next year.
- Clinical bar in B-SUPREME: pevifoscorvir sodium must prove superiority over standard tenofovir at 48 weeks, a test that will not read out until late Q3 2027.
- Rival hepatitis B therapies: competing genetic medicines and functional-cure combinations remain in clinical trials, and their progress will determine the commercial value of a viral-suppression pill.
- Reliance on Amoytop: up to $420 million in potential Greater China milestones depend on the partner's undisclosed clinical and regulatory schedule.
💲 Other KPIs
Cash and investments rose by $0.7 million from June's $30.4 million balance, but fell 68.6% from $99.1 million a year ago. Collecting the $25.0 million Amoytop upfront payment in July offset $24.3 million of underlying cash burn by our math. The balance funds planned operations into the first quarter of 2027.
Overhead spending rose 13.6% from $5.2 million a year ago and increased 4.4% from $5.6 million last quarter. Aligos said the increase was "primarily due to a increase in legal and other related expenses," while stock-based compensation in this line dipped slightly to $0.6 million from $0.7 million a year ago.
Stockholders' equity—assets minus liabilities—shrank from $53.5 million at the end of 2025 and $31.9 million in June as quarterly losses accumulated. Meanwhile, other noncurrent liabilities jumped to $16.3 million from $6.1 million in June, alongside an $8.3 million increase in noncurrent assets.
Reported net loss narrowed 30.7% from $31.5 million a year ago to $21.9 million, or $2.09 per share. Excluding non-cash gains and losses from revaluing 2023 stock warrants, net loss narrowed 19.3% from $27.3 million a year ago to $22.0 million by our math, helped by lower trial costs and $2.8 million of customer revenue.
🔮 Guidance
Raised by one quarter on paper. Aligos now expects its $31.1 million cash balance to fund planned operations "into the first quarter of 2027." The prior statement covered operations through Q4 2026 before counting the $25.0 million July upfront payment from Amoytop, and into Q4 2026 when including it in the first-quarter report. By our math, lower third-quarter research spending stretched the existing liquidity by roughly one to two months.
Unchanged. Management reiterated that topline data for both the 131-patient HBeAg-positive and 114-patient HBeAg-negative cohorts are expected in late Q3 2027. With 70 of the 245 enrolled participants having completed 48 weeks of treatment, the trial schedule is holding steady, though the readout still falls two to three quarters after current cash runs out.
❓ Key Questions
How will Aligos fund the gap to Q3 2027?
Cash of $31.1 million only lasts into the first quarter of 2027, while B-SUPREME data arrive in late Q3 2027. Investors need to know whether management plans an equity raise, debt, or another regional licensing deal before year-end.
What happened to the HBeAg-positive second interim analysis?
Earlier filings projected a second interim analysis in the second half of 2026 after 55 HBeAg-positive patients passed 24 weeks. With 70 patients now past 48 weeks, did the company conduct this review or drop it?
What drove the $10 million jump in noncurrent liabilities?
Other noncurrent liabilities rose from $6.1 million in June to $16.3 million in September, while noncurrent assets rose by $8.3 million. Did Aligos sign a new facility lease or record a long-term licensing liability?
Has Aligos shelved its ALG-055009 liver and obesity pill?
After evaluating out-licensing options since late 2024 and spending just $18 thousand on the program in the second quarter, the third-quarter release omitted ALG-055009 entirely. Is partnering still active, or has the program been terminated?